"Identification of Predictive Factors for Platinum and Immunotherapy Combination Treatment in Small Cell Lung Cancer"

Yeouido St. Mary's Hospital Professor Lim Jeong-uk's Team
Lower Inflammation Levels in Lung Cancer Diagnosis
Higher Effortful Vital Capacity Linked to Longer Survival Period

Professor Jeongwook Lim, Respiratory Lung Cancer Center, Yeouido St. Mary's Hospital.

[Asia Economy Reporter Lee Gwan-joo] A study has found that the 'lung function status at diagnosis' is a key factor in predicting treatment outcomes when combining chemotherapy and immunotherapy for extensive-stage small cell lung cancer.

Professor Lim Jung-wook's team at the Respiratory Lung Cancer Center of Yeouido St. Mary's Hospital, The Catholic University of Korea, announced on the 15th that they confirmed this by analyzing treatment outcomes, chemotherapy side effects, and prognostic factors in patients with extensive-stage small cell lung cancer who received a combination treatment of platinum-based chemotherapy and immunotherapy.

Small cell lung cancer accounts for 13-15% of newly diagnosed lung cancers. Compared to non-small cell lung cancer, it is more aggressive, has a faster proliferation rate, and generally has a poorer prognosis. Furthermore, extensive-stage small cell lung cancer, which is more advanced, has a worse prognosis compared to limited-stage disease.

For 30 years, there were no special treatment options other than platinum-based chemotherapy for extensive-stage small cell lung cancer. Recently, a combination treatment of platinum-based chemotherapy and immunotherapy was introduced in Korea and began to be used as first-line therapy. Although several phase 3 clinical trials have demonstrated superior treatment outcomes compared to existing therapies, domestic treatment outcome data remain insufficient, limiting the ability to predict treatment results.

The research team analyzed data from a total of 41 suitable patients registered at seven hospitals under the Catholic Medical Center (Yeouido St. Mary's, Seoul St. Mary's, Uijeongbu St. Mary's, Bucheon St. Mary's, Eunpyeong St. Mary's, St. Vincent's, and Incheon St. Mary's). The analysis showed that lower inflammation-related markers such as lactate dehydrogenase and C-reactive protein at lung cancer diagnosis, and higher forced vital capacity, were significantly associated with longer survival after starting chemotherapy.

Professor Lim said, "Small cell lung cancer receives less public attention than non-small cell lung cancer, and treating patients at the extensive stage is challenging, but continuous research is necessary for better treatment outcomes." He added, "We plan to conduct follow-up studies to investigate whether treatment outcomes synchronize with improvements in patients' lung function and the relationship between comorbid lung diseases and responses to small cell lung cancer treatment."

This study was published in the recent issue of the international academic journal specializing in thoracic oncology, 'THORACIC CANCER.'

This content was produced with the assistance of AI translation services.